KRAS and non-small cell lung carcinoma: Analyzing high-quality observational RWE phenotypic data alongside genomic mutations and co-mutations in NSCLC may better elucidate how KRAS, SMARCA4 (class 1 and 2), and KRAS/SMARCA4 co-mutations intersect and influence overall patient outcomes and survival, thereby informing future drug development.